Ironwood Pharmaceuticals Inc
IRWD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001446847
In the last 90 days, Ironwood Pharmaceuticals Inc insiders filed 0 open-market purchases and 1 sale; 212 institutions reported holding it in 13F filings for Q2 2026, worth $675.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ironwood Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $578.1K in total
- Insiders trading
- 1
- Net value
- −$578.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ironwood Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Denner Alexander J | Director | 327,549 | Sep 17, 2026 | 4 |
| Silber Jeffrey | SVP, CMO, Head-Res&Drug | 137,036 | Jul 22, 2026 | 1 |
| Silver Ronald | PFO & PAO | 313,680 | Jul 9, 2026 | 5 |
| Currie Mark G | Director | 676,900 | Jun 17, 2026 | 1 |
| McHugh Julie | Director | 250,749 | Jun 17, 2026 | 1 |
| Shepard Jay | Director | 235,036 | Jun 17, 2026 | 1 |
| Kessler Marla L | Director | 229,364 | Jun 17, 2026 | 1 |
| Duane Jon R | Director | 253,820 | Jun 17, 2026 | 1 |
| Moukheibir Catherine | Director | 181,425 | Jun 17, 2026 | 1 |
| MCCOURT Thomas A | Chief Executive Officer | 1,898,838 | Mar 12, 2026 | 2 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug | 658,037 | Mar 12, 2026 | 2 |
| John Minardo | Chief Legal Officer | 500,498 | Mar 12, 2026 | 2 |
| Martini Gregory S. | Chief Financial Officer | 297,213 | Mar 12, 2026 | 2 |
| Gaskins Tammi L | Chief Commercial Officer | 350,350 | Mar 12, 2026 | 3 |
| Sarissa Capital Management LP | 10% Owner | 251,858 | Dec 17, 2025 | 1 |
| Dreyfus Andrew | Director | 228,313 | Jun 12, 2025 | 0 |
| Emany Sravan Kumar | SVP, COO and CFO | 309,572 | Nov 20, 2024 | 0 |
| Davis Andrew | SVP, Chief Business Officer | 284,685 | Nov 20, 2024 | 0 |
| Rickard Jason | SVP, Chief Operating Officer | 376,316 | Mar 10, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 (view filing)4:32 PM ET | Jul 7 | 2 days | Silver RonaldPFO & PAO | SSaleClass A Common Stock | −127.9K | $4.52 | −$578.1K | −29.0%313.7K after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | McHugh JulieDirector | SSaleClass A Common Stock | −21.6K | $3.73 | −$80.5K | −7.9%250.7K after | 10b5-1 |
| Mar 17, 2026 (view filing) | Mar 17 | Same day | Denner Alexander JDirector | SSaleClass A Common Stock | −6.73M | $3.05 | −$20.5M | −42.3%9.19M after | 2 lots |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | Martini Gregory S.Chief Financial Officer | SSaleClass A Common Stock | −21.9K | $3.73 | −$81.9K | −12.0%160.6K after | 2 lots |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | John MinardoChief Legal Officer | SSaleClass A Common Stock | −36.5K | $3.73 | −$136.2K | −9.1%363.9K after | 2 lots |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Shetzline MichaelSVP, CMO, Head-Res&Drug | SSaleClass A Common Stock | −15.6K | $3.81 | −$59.3K | −2.8%538.4K after | |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Shetzline MichaelSVP, CMO, Head-Res&Drug | SSale | +17.0K | $3.66 | +$62.3K | +3.4%521.4K after | |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | Gaskins Tammi LChief Commercial Officer | SSaleClass A Common Stock | −21.5K | $3.73 | −$80.3K | −9.1%213.7K after | 2 lots |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −198.3K | $3.73 | −$739.9K | −11.8%1.49M after | 2 lots |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −24.2K | $3.73 | −$90.2K | −8.7%252.6K after | 2 lots |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −35.4K | $4.60 | −$162.9K | −11.3%276.8K after | 10b5-1 |
| Nov 19, 2025 (view filing) | Nov 17 | 2 days | Gaskins Tammi LChief Commercial Officer | SSaleClass A Common Stock | −6.02K | $3.32 | −$20.0K | −2.5%235.3K after | |
| Aug 13, 2025 (view filing) | Aug 11 | 2 days | Gaskins Tammi LChief Commercial Officer | SSaleClass A Common Stock | −1.32K | $0.84 | −$1.11K | −0.5%241.3K after | |
| Aug 13, 2025 (view filing) | Aug 11 | 2 days | John MinardoChief Legal Officer | SSaleClass A Common Stock | −7.75K | $0.84 | −$6.51K | −1.9%400.4K after | |
| Aug 13, 2025 (view filing) | Aug 11 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −2.85K | $0.84 | −$2.39K | −1.0%276.8K after | |
| Aug 13, 2025 (view filing) | Aug 11 | 2 days | Martini Gregory S.Chief Financial Officer | SSaleClass A Common Stock | −1.26K | $0.84 | −$1.06K | −0.7%182.5K after | |
| May 20, 2025 (view filing) | May 16 | 4 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −13.4K | $0.58 | −$7.74K | −1.2%1.15M after | |
| May 20, 2025 (view filing) | May 16 | 4 days | Gaskins Tammi LChief Commercial Officer | SSaleClass A Common Stock | −2.56K | $0.58 | −$1.49K | −1.0%242.6K after | |
| Feb 12, 2025 (view filing) | Feb 10 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −139.1K | $1.76 | −$244.8K | −10.7%1.16M after | |
| Feb 12, 2025 (view filing) | Feb 10 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −12.0K | $1.76 | −$21.2K | −4.1%279.7K after | |
| Feb 12, 2025 (view filing) | Feb 10 | 2 days | Shetzline MichaelSVP, CMO, Head-Res&Drug | SSaleClass A Common Stock | −41.3K | $1.76 | −$72.6K | −6.9%554.0K after | |
| Feb 12, 2025 (view filing) | Feb 10 | 2 days | John MinardoChief Legal Officer | SSaleClass A Common Stock | −38.9K | $1.76 | −$68.5K | −8.7%408.1K after | |
| Feb 12, 2025 (view filing) | Feb 10 | 2 days | Martini Gregory S.Chief Financial Officer | SSaleClass A Common Stock | −12.1K | $1.76 | −$21.2K | −6.2%183.8K after | |
| Nov 20, 2024 (view filing) | Nov 18 | 2 days | Davis AndrewSVP, Chief Business Officer | SSaleClass A Common Stock | −5.36K | $4.08 | −$21.9K | −1.8%284.7K after | |
| Nov 20, 2024 (view filing) | Nov 18 | 2 days | Emany Sravan KumarSVP, COO and CFO | SSaleClass A Common Stock | −11.0K | $4.08 | −$44.9K | −3.4%309.6K after | |
| Aug 14, 2024 (view filing) | Aug 12 | 2 days | John MinardoChief Legal Officer | SSaleClass A Common Stock | −9.91K | $4.27 | −$42.3K | −3.4%284.7K after | |
| Aug 14, 2024 (view filing) | Aug 12 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −3.11K | $4.27 | −$13.3K | −1.9%158.4K after | |
| Jun 12, 2024 (view filing) | Jun 10 | 2 days | McHugh JulieDirector | SSaleClass A Common Stock | −22.8K | $6.29 | −$143.2K | −14.0%139.5K after | 10b5-1 |
| Jun 10, 2024 (view filing) | Jun 6-7 | 4 days | Moukheibir CatherineDirector | SSaleClass A Common Stock | −80.0K | $6.47 | −$517.7K | −62.2%48.6K after | 2 lots |
| May 22, 2024 (view filing) | May 20 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −67.6K | $6.45 | −$436.1K | −5.6%1.15M after | |
| May 22, 2024 (view filing) | May 20 | 2 days | Davis AndrewSVP, Chief Business Officer | SSaleClass A Common Stock | −22.7K | $6.45 | −$146.6K | −7.3%288.0K after | |
| May 22, 2024 (view filing) | May 20 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −16.1K | $6.45 | −$104.0K | −3.8%413.7K after | |
| May 22, 2024 (view filing) | May 20 | 2 days | John MinardoChief Legal Officer | SSaleClass A Common Stock | −17.4K | $6.45 | −$112.3K | −5.6%294.6K after | |
| Mar 8, 2024 (view filing) | Mar 6 | 2 days | Duane Jon RDirector | PPurchaseClass A Common Stock | +6.92K | $8.70 | +$60.2K | +6.1%121.0K after | |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Emany Sravan KumarSVP, Chief Financial Officer | PPurchaseClass A Common Stock | +10.7K | $9.38 | +$100.2K | +3.7%301.7K after | |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | John MinardoChief Legal Officer | SSaleClass A Common Stock | −47.4K | $15.24 | −$722.1K | −17.4%224.8K after | |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −38.6K | $15.24 | −$588.5K | −10.2%340.5K after | |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −7.91K | $15.24 | −$120.5K | −5.6%134.3K after | |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Davis AndrewSVP, Chief Business Officer | SSaleClass A Common Stock | −9.85K | $15.24 | −$150.1K | −4.5%208.3K after | |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −177.2K | $15.24 | −$2.70M | −17.5%832.8K after | |
| Dec 18, 2023 (view filing) | Dec 14 | 4 days | Kessler Marla LDirector | SSaleClass A Common Stock | −9.93K | $11.19 | −$111.1K | −9.3%96.6K after | 10b5-1 |
| Nov 22, 2023 (view filing) | Nov 20 | 2 days | Davis AndrewSVP, Chief Business Officer | SSaleClass A Common Stock | −3.29K | $9.69 | −$31.9K | −1.5%217.4K after | |
| Sep 18, 2023 (view filing) | Sep 15 | 3 days | Emany Sravan KumarSVP, Chief Financial Officer | PPurchaseClass A Common Stock | +36.1K | $8.32 | +$300.1K | +23.6%188.7K after | |
| Aug 16, 2023 (view filing) | Aug 14 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −1.98K | $10.04 | −$19.8K | −1.5%134.2K after | |
| Aug 16, 2023 (view filing) | Aug 14 | 2 days | John MinardoChief Legal Officer | SSaleClass A Common Stock | −7.04K | $10.04 | −$70.7K | −3.5%192.2K after | |
| Jun 1, 2023 (view filing) | May 30 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −26.6K | $10.70 | −$285.0K | −3.4%758.3K after | 10b5-1 |
| May 24, 2023 (view filing) | May 22 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −36.0K | $10.12 | −$364.3K | −4.4%784.9K after | |
| May 24, 2023 (view filing) | May 22 | 2 days | Shetzline MichaelCMO,SVP,Head-Res&Drug | SSaleClass A Common Stock | −10.3K | $10.12 | −$104.5K | −3.1%321.1K after | |
| May 24, 2023 (view filing) | May 22 | 2 days | Davis AndrewSVP, Chief Business Officer | SSaleClass A Common Stock | −6.30K | $10.12 | −$63.8K | −2.8%219.3K after | |
| May 10, 2023 (view filing) | May 8 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −21.1K | $10.62 | −$224.6K | −2.5%820.9K after |